ÂÜÀòÂÒÂ×

Kevin Fitzgerald is senior vice president, head of research and translational science at Alnylam Pharmaceuticals in Cambridge, MA. He has over 19 years of drug discovery experience. He joined Alnylam in 2005 as an associate director of research after spending 7 years at Bristol-Myers Squibb. He has served in roles of increasing responsibility and leadership since that time. His achievements at Alnylam include leadership of the company's RNAi delivery efforts, resulting in two clinically validated modes of siRNA delivery, and the development of Alnylam’s disease pipeline. He is an inventor on over 50 patents including the majority of Alnylam’s pipeline programs, and the author of over 40 papers including many in prestigious journal’s such as Nature, Cell, and NEJM. He has led multiple programs — including Alnylam’s Inclisiran program — from discovery through pre-clinical development, regulatory submissions, and early clinical development. Kevin received his Bachelor of Science in genetics from Cornell University and his doctorate in molecular biology from Princeton University. He completed his post-doctoral fellowship in oncology at Harvard Medical School.